Our Team

Tom brings more than 36 years of experience as a CEO at both public and private companies. He has translated more than 20 concepts into commercially viable products. He has raised more than $200 million for both public and private companies. Tom began his healthcare career at American Hospital Supply Corp. (now Baxter International), where he held a number of positions with increasing responsibility, including President of its Heyer-Schulte unit. He is a member of the Dean’s Council of the Jacobs School of Engineering at the University of California San Diego and an advisory board member for Enterprise Ireland, Healthcare Angels, and University of California at San Francisco’s Rosenman Institute. Tom co-hosts the Salem Radio Networks’ weekly program, “The Mentors.” He holds a B.S.M.E. degree from the University of Notre Dame and pursued graduate-level coursework in business and finance at the Universities of Minnesota and Chicago

Sam has had a more than 25-year career as a pharmacologist in both large pharmaceutical and early stage biotech companies. He has served in research, research management and executive roles at companies including Biochron Therapeutics, Neurotrope Bioscience, and Sanofi and its predecessor companies. He holds a BSc in Biology from the University of Ottawa, an MSc in Biology from the University of Illinois at Chicago and a PhD in Neuropharmacology from the University of Chicago.

Ephraim brings to Bryologyx more than 17 years’ experience in pharmaceutical product development, with expertise in API development and manufacturing from pilot through commercial scale, and in working with contract manufacturing organizations. He has served at companies including Celgene, Codexis, and Hospira. He holds a PhD in Chemistry from Stony Brook University.

Reza has more than 20 years of broad finance experience in financial/economic consulting, corporate development and financial management. In addition to financial management roles of increasing responsibility, he has led numerous high-profile assignments in valuations, transaction support and sophisticated modeling for strategic planning and financial forecasting. He holds a BA degree from the University of California at Berkley, an MBA from the University of Chicago and pursued post-graduate studies at University of Oxford.

For more than 36 years, John has founded and been a successful investor in more than 50 medical/pharmaceutical companies. Since March 1992, Dr. Abeles has been the Founder, Sole Investor and General Partner of Northlea Partners LLLP, a private venture capital and private capital family office. Dr. Abeles is also the President and founder of MedVest, Inc., which has provided consulting services to health care and high technology companies since 1980. Prior to his career as an investor, he served in senior capacities at several leading healthcare companies, including Sterling Drug, Pfizer and Revlon Healthcare and as a healthcare analyst at Kidder Peabody. Dr. Abeles holds an MD and degree in pharmacology from the University of Birmingham, England. He is a Fellow of the Royal Society of Medicine, London.

Paul is the Bergstrom Professor of Chemistry at Stanford University. Research in his laboratory led to the first practical fully synthetic process for bryostatin-1, which is licensed to the company. His laboratory focuses on chemistry, synthesis, biology, medicine, and materials science using new computational tools, new reactions, reagents, strategies and design. He is a member of the US National Academy of Sciences, a foreign member of the Royal Spanish Academy of Sciences, and a fellow of the American Association for the Advancement of Science and the American Academy of Arts and Sciences. He received his B.S. degree from Wilkes University and his Ph.D. in chemistry from Yale University.

Tom brings more than 36 years of experience as a CEO at both public and private companies. He has translated more than 20 concepts into commercially viable products. He has raised more than $200 million for both public and private companies. Tom began his healthcare career at American Hospital Supply Corp. (now Baxter International), where he held a number of positions with increasing responsibility, including President of its Heyer-Schulte unit. He is a member of the Dean’s Council of the Jacobs School of Engineering at the University of California San Diego and an advisory board member for Enterprise Ireland, Healthcare Angels, and University of California at San Francisco’s Rosenman Institute. Tom co-hosts the Salem Radio Networks’ weekly program, “The Mentors.” He holds a B.S.M.E. degree from the University of Notre Dame and pursued graduate-level coursework in business and finance at the Universities of Minnesota and Chicago

Dr. Grossman has over 25 years of extensive experience leading successful global clinical organizations, and currently serves as Chief Medical Officer (CMO) of Arcus Biosciences. Previously, Dr. Grossman served as CMO of Bellicum Pharmaceuticals, responsible for its clinical development, regulatory affairs, clinical operations, and medical affairs organizations. Dr. Grossman was the Global Group Medical Director for Cancer Immunotherapy at Genentech, and prior to Genentech, held leadership roles in oncology and immunology at AbbVie, Biothera, Baxter Healthcare, and Merck & Co.

Prior to joining the industry, Dr. Grossman held various positions with the Children’s Hospital of Wisconsin/Medical College of Wisconsin where he was Founder and Medical Director of the Clinical Immunodiagnostic and Research Laboratory, Professor for Microbiology and Genetics, and Director of the Hematology/Oncology/Bone Marrow Transplant Division for the Immunodeficiency Transplant Program.

Dr. Grossman holds a B.A. in Biology and Chemistry from University of St. Thomas, St. Paul, Minnesota (Magna Cum Laude) and M.D. and Ph.D. (Immunology) degrees from Washington University School of Medicine’s Medical Scientist Training Program. He completed his medical training in the Division of Pediatric Biology/Medicine at the Washington University School of Medicine.

Michael is Founder and Chairman, SinoCare, a hospital management group based in Beijing. He has more than 40 years of healthcare experience in pharmaceutical research, medtech business development, and hospital delivery system management. He also serves on the board of several healthcare-related corporations that he founded or co-founded in the US and China, including Sinomed and Medical Entrepreneurs II. He also organized and co-founded the International Drug Delivery Society in China, and currently serves as Vice-Chairman of the Society.

Clint is former Chairman and CEO of Abaxis, Inc., a company he led from a start-up to a publicly held company with over $220 million in revenues, to its acquisition in 2018 for $2 billion. He has had a more than 40 year-career in the healthcare industry. In 2007, he was named Forbes Entrepreneur of the Year.

Bruce, who is Senior Counsel at DLA Piper, has for more than 35 years represented business and finance clients in the life sciences industry. He is highly experienced in equity and debt financing, licensing and distribution, strategic alliances, joint ventures, and mergers and acquisitions, as well as general counseling issues, representing both startups and large multinational corporations.

Terry is a leading cancer researcher and expert in immuno-oncology and pediatric cancers. He is among the first to investigate CAR-T directed at CD19 for refractory pediatric acute lymphoblastic leukemia (now approved).

Cohava is a leader in the discovery and development of immune therapeutics and diagnostics for cancer, autoimmune disease, allergies and infectious diseases. She has authored more than 70 patents/patent applications.

Crystal is a leader in basic and translational cancer research, immuno-therapy and immuno-oncology clinical trials. She is a former Chief of the NCI’s Pediatric Oncology Branch.

Dan is a clinician and cancer drug development leader. He has been involved in the development of more than 12 FDA approved cancer drugs. He is an author on more than 675 papers and is past President of American Assn. for Cancer Research (AACR).

Steven has been engaged in HIV care and clinical programs since 1993. He is an expert on HIV-associated immune dysfunction and its impact on HIV persistence and health during antiretroviral therapy. He is an author on more than 400 publications.

Bob is an expert on latent HIV infection and development of therapeutics targeting latent viral reservoirs. He is a Member of the National Academy of Sciences and an Investigator in the Howard Hughes Medical Institute. He is a recipient of the Distinguished Clinical Scientist Award (Doris Duke Charitable Foundation).

Paul has been a leading HIV/AIDS clinician and clinical researcher leader for 30+ years. He has led many HIV research and global health initiatives. He serves as Director of the amfAR Institute for HIV Cure; and as a Member of the National Academy of Medicine.

Jerry is an expert on HIV infection and model systems and their application to human therapeutic development. He is Director of the Center for AIDS Research and Co-Director of the UCLA AIDS Institute. He is an author on more than 150 scientific publications.